Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution that ...

Welcome to the Viking Therapeutics Fourth Quarter and Full ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Please go ahead, Stephanie. Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) gapped down before the market opened on Thursday following a dissappointing earnings announcement. The stock had previously closed at $ ...

VIKING THERAPEUTICS ($VKTX) posted quarterly earnings results on Wednesday, February 5th. The company reported earnings of -$0.32 per share, missing estimates of -$0. ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...